HighTower Advisors LLC Raises Position in Merck & Co., Inc. $MRK

HighTower Advisors LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 1.2% in the second quarter, Holdings Channel reports. The firm owned 3,679,920 shares of the company’s stock after buying an additional 44,516 shares during the period. HighTower Advisors LLC’s holdings in Merck & Co., Inc. were worth $472,870,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $31,000. Finally, High Note Wealth LLC increased its holdings in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP David Michael Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. This represents a 24.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 over the last ninety days. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Stock Up 2.3%

NYSE MRK opened at $152.43 on Friday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $154.49. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The business’s fifty day simple moving average is $128.09 and its 200-day simple moving average is $121.23. The firm has a market cap of $376.07 billion, a PE ratio of 121.94, a P/E/G ratio of 6.58 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the previous year, the company posted $2.13 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on MRK shares. Wells Fargo & Company raised their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday. CICC Research started coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $144.10.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.